Posted On: 09/09/2014 11:01:03 PM
Post# of 30066
I agree with you now that I've had more time to think about it. As separate entities, the company would have to purchase or license any new NF asset discovered. By spinning out the diagnostic division instead, the holding company would own all new NF assets.
That raises the question of how to fund MANF going forward, since LymPro revenue would no longer be accessible to the company. While grant money will help, it's not going to be enough to fund company operations and the cost of developing each new asset. That leaves partnership money for one or more of the various MANF treatments until they begin to generate revenue.
Therefore, any spin-off is likely be after receiving significant partnership money for one of the MANF targeted diseases. Does this make sense?
That raises the question of how to fund MANF going forward, since LymPro revenue would no longer be accessible to the company. While grant money will help, it's not going to be enough to fund company operations and the cost of developing each new asset. That leaves partnership money for one or more of the various MANF treatments until they begin to generate revenue.
Therefore, any spin-off is likely be after receiving significant partnership money for one of the MANF targeted diseases. Does this make sense?
(0)
(0)
